{
    "body": "Is nivolumab used for treatment of Non\u2013Small-Cell Lung Cancer?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26028407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25897158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24685885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25704439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25965365", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25496336"
    ], 
    "ideal_answer": [
        "Yes, nivolumab used for treatment of Non\u2013Small-Cell Lung Cancer."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002289", 
        "http://www.disease-ontology.org/api/metadata/DOID:3908"
    ], 
    "type": "yesno", 
    "id": "56bb68a5ac7ad1001900000a", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 428, 
            "text": "BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1610, 
            "offsetInEndSection": 1855, 
            "text": "CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 342, 
            "offsetInEndSection": 741, 
            "text": "Agents currently in active clinical development for lung cancer include ipilimumab, which modulates the cytotoxic T-lymphocyte-associated antigen 4 pathway, and multiple agents targeting the programmed death protein 1 (PD-1) pathway, both anti-PD-1 compounds (nivolumab, pembrolizumab [MK-3475]) and those that target programmed death ligand 1 (PD-L1), a key ligand for PD-1 (BMS-936559, MPDL3280A).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685885", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 180, 
            "text": "Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 318, 
            "offsetInEndSection": 666, 
            "text": "We report overall survival (OS), response durability, and long-term safety in patients with non-small-cell lung cancer (NSCLC) receiving nivolumab in this trial.PATIENTS AND METHODS: Patients (N = 129) with heavily pretreated advanced NSCLC received nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks in 8-week cycles for up to 96 weeks. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1545, 
            "offsetInEndSection": 1752, 
            "text": "CONCLUSION: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC. Randomized clinical trials with nivolumab in advanced NSCLC are ongoing.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 261, 
            "text": "Two PD-1 inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, both demonstrated positive results in phase I trials of previously treated patients with non-small cell lung cancer, reported at the World Conference on Lung Cancer in Sydney, Australia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 718, 
            "offsetInEndSection": 923, 
            "text": "Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 270, 
            "text": "Two PD-1 inhibitors, Bristol-Myers Squibb&apos;s nivolumab and Merck&apos;s MK-3475, both demonstrated positive results in phase I trials of previously treated patients with non-small cell lung cancer, reported at the World Conference on Lung Cancer in Sydney, Australia", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 677, 
            "offsetInEndSection": 936, 
            "text": "Nivolumab, pembrolizumab (formerly known as MK-3475 and lambrolizumab), and pidilizumab are anti-PD-1 antibodies in clinical development for melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, lymphoma, and several other cancers", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25965365", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 80, 
            "text": "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 196, 
            "text": "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 290, 
            "text": " Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1708, 
            "offsetInEndSection": 2011, 
            "text": " Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439", 
            "endSection": "abstract"
        }
    ]
}